MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

ENANTA PHARMACEUTICALS INC

Geschlossen

BrancheGesundheitswesen

10.33 -2.73

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.07

Max

10.9

Schlüsselkennzahlen

By Trading Economics

Einkommen

4.4M

-18M

Verkäufe

3.4M

18M

Gewinnspanne

-99.678

Angestellte

131

EBITDA

5.6M

-15M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+72.76% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

24. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

185M

324M

Vorheriger Eröffnungskurs

13.06

Vorheriger Schlusskurs

10.33

Nachrichtenstimmung

By Acuity

35%

65%

104 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

ENANTA PHARMACEUTICALS INC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Okt. 2025, 23:30 UTC

Heiße Aktien

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2. Okt. 2025, 21:21 UTC

Ergebnisse

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3. Okt. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2. Okt. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2. Okt. 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2. Okt. 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2. Okt. 2025, 22:54 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Scales's JV Buyout Lauded by Bull -- Market Talk

2. Okt. 2025, 22:54 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Forex and Fixed Income Roundup: Market Talk

2. Okt. 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2. Okt. 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Okt. 2025, 21:17 UTC

Akquisitionen, Fusionen, Übernahmen

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2. Okt. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

2. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Okt. 2025, 20:49 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2. Okt. 2025, 20:00 UTC

Akquisitionen, Fusionen, Übernahmen

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2. Okt. 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2. Okt. 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2. Okt. 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2. Okt. 2025, 18:43 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer-Vergleich

Kursveränderung

ENANTA PHARMACEUTICALS INC Prognose

Kursziel

By TipRanks

72.76% Vorteil

12-Monats-Prognose

Durchschnitt 18.33 USD  72.76%

Hoch 25 USD

Tief 9 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ENANTA PHARMACEUTICALS INC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

5

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

5.04 / 5.44Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

No Evidence

Stimmung

By Acuity

104 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
help-icon Live chat